NSE - Delayed Quote INR

Cipla Limited (CIPLA.NS)

Compare
1,529.10 +0.10 (+0.01%)
At close: 3:30:00 PM GMT+5:30
Loading Chart for CIPLA.NS
DELL
  • Previous Close 1,529.00
  • Open 1,531.95
  • Bid --
  • Ask --
  • Day's Range 1,518.70 - 1,547.85
  • 52 Week Range 1,266.20 - 1,702.05
  • Volume 1,578,153
  • Avg. Volume 2,403,520
  • Market Cap (intraday) 1.235T
  • Beta (5Y Monthly) 0.34
  • PE Ratio (TTM) 27.63
  • EPS (TTM) 55.35
  • Earnings Date Jan 23, 2025 - Jan 27, 2025
  • Forward Dividend & Yield 13.00 (0.85%)
  • Ex-Dividend Date Aug 2, 2024
  • 1y Target Est 1,629.03

Cipla Limited, together with its subsidiaries, engages in the manufacture, development, sale, and distribution of pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer's disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. The company is also involved in the consumer healthcare, biosimilars, and specialty businesses. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.

www.cipla.com

27,764

Full Time Employees

March 31

Fiscal Year Ends

Recent News: CIPLA.NS

View More

Performance Overview: CIPLA.NS

Trailing total returns as of 1/1/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

CIPLA.NS
0.51%
S&P BSE SENSEX
0.33%

1-Year Return

CIPLA.NS
23.73%
S&P BSE SENSEX
8.68%

3-Year Return

CIPLA.NS
66.83%
S&P BSE SENSEX
34.77%

5-Year Return

CIPLA.NS
233.78%
S&P BSE SENSEX
90.30%

Compare To: CIPLA.NS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: CIPLA.NS

View More

Valuation Measures

As of 12/31/2024
  • Market Cap

    1.24T

  • Enterprise Value

    1.15T

  • Trailing P/E

    27.61

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    4.72

  • Price/Book (mrq)

    4.35

  • Enterprise Value/Revenue

    4.40

  • Enterprise Value/EBITDA

    16.18

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    17.04%

  • Return on Assets (ttm)

    10.85%

  • Return on Equity (ttm)

    16.74%

  • Revenue (ttm)

    262.64B

  • Net Income Avi to Common (ttm)

    44.75B

  • Diluted EPS (ttm)

    55.35

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    87.08B

  • Total Debt/Equity (mrq)

    1.62%

  • Levered Free Cash Flow (ttm)

    46.22B

Research Analysis: CIPLA.NS

View More

People Also Watch